Gastrointestinal Cancer | Specialty

Dr. Eng on the FDA Approval of Nivolumab Plus Ipilimumab in CRC

July 11th 2018

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses the FDA approval of nivolumab (Opdivo) plus ipilimumab (Yervoy) in patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) following progression on a fluoropyrimidine, oxaliplatin, and irinotecan.

FDA Approves Nivolumab/Ipilimumab for MSI-H/dMMR Colorectal Cancer

July 11th 2018

The FDA has approved the combination of nivolumab and ipilimumab for the treatment of adult and pediatric patients 12 years and older with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer following progression on a fluoropyrimidine, oxaliplatin, and irinotecan.

Dr. Ulahannan on the PRODIGE Trial in Pancreatic Cancer

July 11th 2018

Susanna Ulahannan, MD, assistant professor, Section of Hematology/Oncology, associate director, Oklahoma TSET Phase I Program, Stephenson Cancer Center, The University of Oklahoma, discusses the PRODIGE trial in pancreatic cancer.

Experts Anticipate a Growing Menu of Frontline Options in Liver Cancer

July 4th 2018

Panelists review data for lenvatinib (Lenvima), and novel drugs under investigation in the second line for HCC, such as cabozantinib (Cabometyx/Cometriq) and pembrolizumab (Keytruda).

Marshall Makes the Case for Molecular Sorting in Gastrointestinal Disease

July 3rd 2018

Oncologists have been slow to introduce targeted and immune therapies into the treatment of gastrointestinal cancers, but that is changing, and poor patient survival statistics call for a continuation of this trend, according to John L. Marshall, MD.

Expert Provides Clarity on Treatment of Advanced HCC

June 28th 2018

Mitesh J. Borad, MD, discusses liver-directed therapies, systemic therapy, and the management of liver cancer.

Dr. Bekaii-Saab on the ReDOS Study in Metastatic Colorectal Cancer

June 27th 2018

Tanios Bekaii-Saab, MD, medical oncologist, Mayo Clinic, discusses the ReDOS study of regorafenib (Stivarga) in patients with metastatic colorectal cancer (mCRC).

Dr. Schwark on Microsatellite Instability and Lynch Syndrome

June 27th 2018

Alicia Latham Schwark, MD, medical genetics fellow, Memorial Sloan Kettering Cancer Center, discusses a study exploring microsatellite instability (MSI) and how it relates to Lynch syndrome across all tumor types. The findings were presented at the 2018 ASCO Annual Meeting.

Expert Highlights Ongoing Research and Challenges in Pancreatic Cancer

June 27th 2018

Ramesh K. Ramanathan, MD, discusses sequencing strategies and emerging therapeutic targets in pancreatic cancer.

Grothey Grapples With Treatment Options in mCRC

June 26th 2018

Axel Grothey, MD, discusses sidedness and first- and second-line treatments for patients with metastatic colorectal cancer.

Trifluridine/Tipiracil Plus Bevacizumab Improves Survival in Patients With mCRC

June 26th 2018

Patients with metastatic colorectal cancer who are not eligible for chemotherapy or surgical resection may have a new first-line treatment option.

Improving the Management of Advanced Gastric/GEJ Cancer

June 26th 2018

Advanced Gastric/GEJ Cancer: Sequencing Treatment

June 26th 2018

VEGF and PD-1 Inhibition in Advanced Gastric/GEJ Cancer

June 26th 2018

Approaching Treatment for Recurrent Gastric/GEJ Cancer

June 26th 2018

Goals of Therapy in Metastatic Gastric/GEJ Cancer

June 26th 2018

Selecting Perioperative Therapy in Gastric/GEJ Cancer

June 26th 2018

Analyzing Potential Therapies in Gastric/GEJ Cancer

June 26th 2018

Gastric/GEJ Cancer: Moving the Field Forward

June 26th 2018

Metastatic Gastric/GEJ Cancer: Multiple Lines of Therapy

June 26th 2018